Evidence map›Paper›PMID 32248797›Full record

ArticleBMC cancer2020

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.

Motomasa Furuse, Hiroko Kuwabara, Naokado Ikeda, Yasuhiko Hattori, Tomotsugu Ichikawa, Naoki Kagawa, Kenichiro Kikuta, Sho Tamai, Mitsutoshi Nakada, Toshihiko Wakabayashi and 4 more

Abstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Immunotherapy in central nervous system tumors.International journal of surgery (London, England) · 2025
    Review
  5. Review
  6. Review
  7. Novel Therapies in Primary Central Nervous System Lymphoma.Clinical pharmacology : advances and applications · 2025
    Review
  8. Article
  9. Article
  10. Updates of primary central nervous system lymphoma.Therapeutic advances in hematology · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Primary central nervous system lymphoma.Nature reviews. Disease primers · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Central Nervous System Lymphoma: Novel Therapies.Current treatment options in oncology · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Motomasa FuruseDepartment of Neurosurgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Takatsuki, Osaka, 569-8686, Japan.
Hiroko KuwabaraDepartment of Pathology, Osaka Medical College, Osaka, Japan.
Naokado IkedaDepartment of Neurosurgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Takatsuki, Osaka, 569-8686, Japan.
Yasuhiko HattoriDepartment of Neurological Surgery, Okayama University, Okayama, Japan.
Tomotsugu IchikawaDepartment of Neurological Surgery, Okayama University, Okayama, Japan.
Naoki KagawaDepartment of Neurosurgery, Osaka University, Osaka, Japan.
Kenichiro KikutaDepartment of Neurosurgery, University of Fukui School of Medical Science, Fukui, Japan.
Sho TamaiDepartment of Neurosurgery, Kanazawa University, Kanazawa, Japan.
Mitsutoshi NakadaDepartment of Neurosurgery, Kanazawa University, Kanazawa, Japan.
Toshihiko WakabayashiDepartment of Neurosurgery, Nagoya University, Nagoya, Japan.
Masahiko WanibuchiDepartment of Neurosurgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Takatsuki, Osaka, 569-8686, Japan.
Toshihiko KuroiwaDepartment of Neurosurgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Takatsuki, Osaka, 569-8686, Japan.
Yoshinobu HiroseDepartment of Pathology, Osaka Medical College, Osaka, Japan.
Shin-Ichi MiyatakeDepartment of Neurosurgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Takatsuki, Osaka, 569-8686, Japan. neu070@osaka-med.ac.jp.ORCID https://orcid.org/0000-0001-8056-1016

Funding

Bristol-Myers Squibb noneChugai Pharmaceutical noneIchiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care noneOno Pharmaceutical (JP) none
6 · The paper itself

Abstract

backgroundThe prevalence of programmed death-ligand 1 (PD-L1) and PD-L2 expression on tumor cells and tumor-infiltrating immune cells in primary central nervous system lymphoma (PCNSL) remains unclear. In the present study, we analyzed needle biopsy and craniotomy specimens of patients with PCNSL to compare the PD-L1 and PD-L2 levels in the tumor and surrounding (peritumoral) tissue. We also assessed the correlation between biological factors and the prognostic significance of PD-L1 and PD-L2 expression.

methodsWe retrospectively analyzed the cases of 70 patients histologically diagnosed with PCNSL (diffuse large B-cell lymphoma). Immunohistochemistry for CD20, CD68, PD-L1, and PD-L2 was performed. In cases with specimens taken by craniotomy, the percentages of PD-L1- and PD-L2-positive macrophages were evaluated in both tumor and peritumoral tissue. The Kaplan-Meier method with log-rank test and Cox proportional hazard model were used for survival analysis.

resultsThe tumor cells expressed little or no PD-L1 and PD-L2, but macrophages expressed PD-L1 and PD-L2 in most of the patients. The median percentage of PD-L2-positive cells was significantly higher among peritumoral macrophages (32.5%; 95% CI: 0-94.6) than intratumoral macrophages (27.5%; 95% CI: 0-81.1, p = 0.0014). There was a significant correlation between the percentages of PD-L2-positive intratumoral macrophages and PD-L2-positive peritumoral macrophages (p = 0.0429), with very low coefficient correlation (ρ = 0.098535). PD-L1 expression on macrophages was significantly associated with biological factors (intratumoral macrophages: better KPS, p = 0.0008; better MSKCC score, p = 0.0103; peritumoral macrophages: low proportion of LDH elevation, p = 0.0064) and longer OS (for intratumoral macrophages: high PD-L1 = 60 months, 95% CI = 30-132.6; low PD-L1 = 24 months, 95% CI = 11-48; p = 0.032; for peritumoral macrophages: high PD-L1 = 60 months, 95% CI = 30.7-NR; low PD-L1 = 14 months, 95% CI = 3-26). PD-L1 expression on peritumoral macrophages was strongly predictive of a favorable outcome (HR = 0.30, 95% CI = 0.12-0.77, p = 0.0129).

conclusionsMacrophages in intratumoral and peritumoral tissue expressed PD-L1 and PD-L2 at a higher rate than tumor cells. PD-L1 expression, especially on peritumoral macrophages, seems to be an important prognostic factor in PCNSL. Future comprehensive analysis of checkpoint molecules in the tumor microenvironment, including the peritumoral tissue, is warranted.

Indexed as

Tumor MicroenvironmentAgedB7-H1 AntigenBiomarkers, TumorCentral Nervous System NeoplasmsFemaleFollow-Up StudiesHumansLymphocytes, Tumor-InfiltratingLymphoma, Large B-Cell, DiffuseMacrophagesMaleMiddle AgedPrognosisProgrammed Cell Death 1 Ligand 2 ProteinRetrospective StudiesB7-H1 AntigenBiomarkers, TumorCD274 protein, humanPDCD1LG2 protein, humanProgrammed Cell Death 1 Ligand 2 ProteinMacrophagePD-L1PD-L2Primary central nervous system lymphomaTumor microenvironment

Identifiers

PMID32248797
PMCPMC7132991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.